• Our Solution
    • Physicians
    • Patients
  • About Artrya
    • Who we are
    • Leadership Team
    • Board of Directors
    • Careers
  • Investor Relations
    • Overview
    • ASX Announcements
    • Corporate Governance
    • Company Research
  • Contact Us
Request a demonstration

Artrya Update December 2021

Notice of Initial Substantial Holder – John Barrington

Initial Director’s Interest Notice – John Konstantopoulos

Notice of Initial Substantial Holder – John Konstantopoulos

Notice of Initital Substantial Holder – Artrya Limited

Initial Director’s Interest Notice – Bernie Ridgeway

Initial Director’s Interest Notice – John Barrington AM

Cardiac imaging software company Artrya Lists on ASX

Employee Option Plan 2019

Top 20 Holders

1 2 3 Next

Precise diagnosis. Personalized treatment.
Preventative care.

Choose Artrya as your trusted clinical partner.

Contact us today
Coronary artery disease.
We see you.

Sign up to our newsletter

Request a Demo
Contact Us

About Artrya
Investor Relations

Location
1257 Hay Street, West Perth, 6005
Follow us
X
LinkedIn

Salix Coronary Anatomy is listed on the Australian Register of Therapeutic Goods, ID 347719.  Salix Coronary Anatomy USA product (K243038) is cleared in the USA. 
For the availability of Salix in the EU, UK, US or other jurisdictions, please contact us.

© 2025, Artrya. All rights reserved. Privacy Policy Terms and Conditions Indications for Use